HC Wainwright Forecasts IN8bio’s Q2 Earnings (NASDAQ:INAB)

IN8bio, Inc. (NASDAQ:INAB) – Investment analysts at HC Wainwright raised their Q2 2026 EPS estimates for IN8bio in a report issued on Monday, May 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.61) for the quarter, up from their prior estimate of ($0.68). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for IN8bio’s Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.77) EPS, FY2026 earnings at ($2.10) EPS, FY2027 earnings at ($1.51) EPS, FY2028 earnings at ($0.44) EPS, FY2029 earnings at $0.27 EPS and FY2030 earnings at $0.69 EPS.

IN8bio (NASDAQ:INAB) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.33.

A number of other research analysts also recently issued reports on INAB. Zacks Research raised shares of IN8bio to a “hold” rating in a research report on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, IN8bio presently has a consensus rating of “Hold” and a consensus price target of $4.00.

IN8bio Trading Down 1.5%

INAB opened at $1.60 on Wednesday. The company has a market capitalization of $15.76 million, a price-to-earnings ratio of -0.61 and a beta of 0.08. IN8bio has a 12-month low of $1.17 and a 12-month high of $5.61. The business’s fifty day simple moving average is $1.59 and its 200-day simple moving average is $1.80.

Institutional Trading of IN8bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. 683 Capital Management LLC purchased a new position in shares of IN8bio in the fourth quarter worth about $1,696,000. Captrust Financial Advisors acquired a new stake in IN8bio in the 4th quarter valued at about $43,000. Alyeska Investment Group L.P. raised its holdings in IN8bio by 1,060.8% in the 4th quarter. Alyeska Investment Group L.P. now owns 957,484 shares of the company’s stock valued at $2,231,000 after acquiring an additional 875,000 shares during the last quarter. HRT Financial LP purchased a new position in IN8bio in the 4th quarter worth approximately $34,000. Finally, Franklin Resources Inc. boosted its holdings in shares of IN8bio by 381.6% during the 4th quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after purchasing an additional 724,637 shares during the last quarter. Institutional investors and hedge funds own 92.05% of the company’s stock.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.